Nanomedicine for cancer patient‐centered care DOI Creative Commons
Carlo Sorrentino, Stefania L. Ciummo, Cristiano Fieni

и другие.

MedComm, Год журнала: 2024, Номер 5(11)

Опубликована: Окт. 20, 2024

Abstract Cancer is a leading cause of morbidity and mortality worldwide, an increase in incidence estimated the next future, due to population aging, which requires development highly tolerable low‐toxicity cancer treatment strategies. The use nanotechnology tailor treatments according genetic immunophenotypic characteristics patient's tumor, allow its targeted release, can meet this need, improving efficacy minimizing side effects. Nanomedicine‐based approach for diagnosis rapidly evolving field. Several nanoformulations are currently clinical trials, some have been approved marketed. However, their large‐scale production still hindered by in‐depth debate involving ethics, intellectual property, safety health concerns, technical issues, costs. Here, we survey key approaches, with specific reference organ‐on chip technology, cutting‐edge tools, such as CRISPR/Cas9 genome editing, through nanosystems needs personalized diagnostics therapy patients. An update provided on nanopharmaceuticals marketed those undergoing trials. Finally, discuss emerging avenues field challenges be overcome transfer nano‐based precision oncology into daily life.

Язык: Английский

Post-Translational Modifications of Proteins Orchestrate All Hallmarks of Cancer DOI Creative Commons
Pathea Bruno,

Aneeta Arshad,

Maria-Raluca Gogu

и другие.

Life, Год журнала: 2025, Номер 15(1), С. 126 - 126

Опубликована: Янв. 18, 2025

Post-translational modifications (PTMs) of proteins dynamically build the buffering and adapting interface between oncogenic mutations environmental stressors, on one hand, cancer cell structure, functioning, behavior. Aberrant PTMs can be considered as enabling characteristics long they orchestrate all malignant variability in proteome cells, cancer-associated tumor microenvironment (TME). On other enhance anticancer mechanisms tumoral ecosystem or sustain beneficial effects oncologic therapies through degradation inactivation carcinogenic or/and activation tumor-suppressor proteins. In this review, we summarized analyzed a wide spectrum involved regulatory that drive tumorigenesis, genetic instability, epigenetic reprogramming, events metastatic cascade, cytoskeleton extracellular matrix (ECM) remodeling, angiogenesis, immune response, tumor-associated microbiome, metabolism rewiring most important hallmarks cancer. All develop due to proteins, which modulate gene transcription, intracellular signaling, protein size, activity, stability localization, trafficking, secretion, half-life, protein–protein interactions (PPIs). associated with exploited better understand underlying molecular heterogeneous chameleonic disease, find new biomarkers progression prognosis, personalize oncotherapies, discover targets for drug development.

Язык: Английский

Процитировано

2

Triple-Negative Breast Cancer Progression and Drug Resistance in the Context of Epithelial–Mesenchymal Transition DOI Open Access
Ewa Błaszczak, Paulina Miziak, Adrian Odrzywolski

и другие.

Cancers, Год журнала: 2025, Номер 17(2), С. 228 - 228

Опубликована: Янв. 12, 2025

Triple-negative breast cancer (TNBC) is one of the most difficult subtypes to treat due its distinct clinical and molecular characteristics. Patients with TNBC face a high recurrence rate, an increased risk metastasis, lower overall survival compared other subtypes. Despite advancements in targeted therapies, traditional chemotherapy (primarily using platinum compounds taxanes) continues be standard treatment for TNBC, often limited long-term efficacy. tumors are heterogeneous, displaying diverse mutation profile considerable chromosomal instability, which complicates therapeutic interventions. The development chemoresistance frequently associated process epithelial–mesenchymal transition (EMT), during epithelial tumor cells acquire mesenchymal-like phenotype. This shift enhances metastatic potential, while simultaneously reducing effectiveness chemotherapeutics. It has also been suggested that EMT plays central role stem cells. Hence, there growing interest exploring small-molecule inhibitors target as future strategy overcoming resistance improving outcomes patients TNBC. review focuses on progression drug emphasis these processes. We present TNBC-specific EMT-related features, key protein markers, various signaling pathways involved. discuss important mechanisms factors related within context EMT, highlighting improve patients’ outcomes.

Язык: Английский

Процитировано

1

Roles of Post-Translational Modifications of Transcription Factors Involved in Breast Cancer Hypoxia DOI Creative Commons

Logan Seymour,

Niyogushima Nuru,

Kaya R. Johnson

и другие.

Molecules, Год журнала: 2025, Номер 30(3), С. 645 - 645

Опубликована: Фев. 1, 2025

BC is the most commonly diagnosed cancer and second leading cause of death among women worldwide. Cellular stress a condition that leads to disrupted homeostasis by extrinsic intrinsic factors. Among other stressors, hypoxia driving force for breast (BC) progression general hallmark solid tumors. Thus, intratumoral an important determinant invasion, metastasis, treatment failure, prognosis, patient mortality. Acquisition epithelial–mesenchymal transition (EMT) phenotype also consequence tumor hypoxia. The cellular response mainly regulated signaling pathway, governed hypoxia-inducible factors (HIFs), HIF1α. HIFs are family transcription (TFs), which induce expression target genes involved in cell survival proliferation, metabolic reprogramming, angiogenesis, resisting apoptosis, metastasis. HIF1α cooperates with large number TFs. In this review, we focused on crosstalk cooperation between TFs BC. We identified cluster TFs, proposed as HIF1α-TF interactome, orchestrates hypoxia, due their post-translational modifications (PTMs), including phosphorylation/dephosphorylation, ubiquitination/deubiquitination, SUMOylation, hydroxylation, acetylation, S-nitrosylation, palmitoylation. PTMs these HIF1α-related drive stability activity, degradation turnover, bidirectional translocation cytoplasm or plasma membrane nucleus cells, well transcription/activation proteins encoded oncogenes inactivation suppressor genes. Consequently, interactome crucial regulatory mechanisms oxygen deprivation cells.

Язык: Английский

Процитировано

0

Study on the Effect of Deer Bone in Improving Rheumatoid Arthritis Based on the “Drug-Target-Pathway” Association Network DOI
Y.-L. Li, Jiakui Li, Yue Teng

и другие.

Journal of Ethnopharmacology, Год журнала: 2025, Номер unknown, С. 119684 - 119684

Опубликована: Март 1, 2025

Язык: Английский

Процитировано

0

Antitumor effects of dauricine on sorafenib-treated human lung cancer cell lines via modulation of HIF-1α signaling pathways DOI Creative Commons

Eman K Teleb,

Radwa A. Mehanna,

Nagwa M. Assem

и другие.

Medical Oncology, Год журнала: 2025, Номер 42(5)

Опубликована: Апрель 9, 2025

Язык: Английский

Процитировано

0

The Regulation of Trace Metal Elements in Cancer Ferroptosis DOI Creative Commons

Xiaoyan Wang,

Yuanyuan Xue, Lei Chang

и другие.

Advanced Biology, Год журнала: 2025, Номер unknown

Опубликована: Апрель 9, 2025

Abstract Ferroptosis, as novel type of regulated cell death that has garnered widespread attention over the past decade, witnessed continuous discovery an increasing number regulatory mechanisms. Trace metal elements play a multifaceted and crucial role in oncology. Interestingly, it been increasingly evident these elements, such copper, are involved regulation iron accumulation, lipid peroxidation antiferroptotic systems, suggesting existence “nonferrous” mechanisms ferroptosis. In this review, comprehensive overview composition mechanism ferroptosis is provided. The interaction between copper metabolism (including cuproptosis) cancer, well roles other trace (such zinc, manganese, cobalt, molybdenum) specifically focused. Furthermore, applications nanomaterials based on metals cancer therapy also reviewed potential strategies for co‐targeting cuproptosis explored. Nevertheless, light intricate ambiguous nature interactions, ongoing research essential to further elucidate ferroptosis, thereby facilitating development therapeutic targets approaches treatment.

Язык: Английский

Процитировано

0

FTO-Mediated m6A Demethylation of OTUB1 Stabilizes SLC7A11 to Alleviate Ferroptosis in Cerebral Ischemia/Reperfusion Injury DOI Creative Commons
Youjin Shen, Wentao Liu, Zhuangzhi Zhou

и другие.

Journal of Stroke and Cerebrovascular Diseases, Год журнала: 2025, Номер unknown, С. 108316 - 108316

Опубликована: Апрель 1, 2025

Язык: Английский

Процитировано

0

Nanomedicine for cancer patient‐centered care DOI Creative Commons
Carlo Sorrentino, Stefania L. Ciummo, Cristiano Fieni

и другие.

MedComm, Год журнала: 2024, Номер 5(11)

Опубликована: Окт. 20, 2024

Abstract Cancer is a leading cause of morbidity and mortality worldwide, an increase in incidence estimated the next future, due to population aging, which requires development highly tolerable low‐toxicity cancer treatment strategies. The use nanotechnology tailor treatments according genetic immunophenotypic characteristics patient's tumor, allow its targeted release, can meet this need, improving efficacy minimizing side effects. Nanomedicine‐based approach for diagnosis rapidly evolving field. Several nanoformulations are currently clinical trials, some have been approved marketed. However, their large‐scale production still hindered by in‐depth debate involving ethics, intellectual property, safety health concerns, technical issues, costs. Here, we survey key approaches, with specific reference organ‐on chip technology, cutting‐edge tools, such as CRISPR/Cas9 genome editing, through nanosystems needs personalized diagnostics therapy patients. An update provided on nanopharmaceuticals marketed those undergoing trials. Finally, discuss emerging avenues field challenges be overcome transfer nano‐based precision oncology into daily life.

Язык: Английский

Процитировано

2